CellWell record HH-227007
Insurance denials of cancer care: Insights from Medicare claims appeals
Youngmin Kwon; Kenji Aoki; Shelley A. Jazowski; Xin Yang Hu; Stacie B. Dusetzina; Lindsay M. Sabik; K. Robin Yabroff; Zheng Zhiyuan
JCO Oncology Practice ยท 2025
In plain language
In Medicare Advantage prescription drug appeals for cancer treatments, over 17 percent of initially denied prior authorization claims were successfully overturned on appeal.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-227007
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.